Printed From BioPortfolio.com

ImmuPharma completes phase III Lupuzor study; on track to publish top-line date this quarter

02:27 EST 18 Jan 2018 | Proactive Investors

The last of the 200 patients has had their final assessment and the data is now being processed and analysed

Original Article: ImmuPharma completes phase III Lupuzor study; on track to publish top-line date this quarter

Proactive Investors

More From BioPortfolio on "ImmuPharma completes phase III Lupuzor study; on track to publish top-line date this quarter"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Advertisement

News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Ad Here

BioPortfolio Limited

Social Media

Publish Content

Agreements

Tools

Help

This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio.
All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd.